Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ACET, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| ADI-212 | Prostate Cancer Metastatic | Phase 1/2 · NCT07793435 | Not yet recruiting |
| Allogeneic Anti-CD70 CAR/dnTGF-BRII-expr | Clear Cell Renal Cell Carcinoma | Phase 1/2 · NCT06480565 | Active not recruiting |
| Fludarabine | Clear Cell Renal Cell Carcinoma | Phase 1/2 · NCT06480565 | Active not recruiting |
| Prulacabtagene Leucel (ADI-001) | Rheumatoid Arthritis (RA) | Phase 1 · NCT07100873 | Recruiting |
Also used in these trials (approved or third-party drugs, not ACET's own candidates): Cyclophosphamide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ACET holds $118.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $20.7M/quarter from operations, an estimated runway of 17.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 43 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ACET files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. 10% owner · +1.40M options |
Insider | 935,486 | 9.99% | 2026-06-30 |
| ORBIMED ADVISORS LLC 10% owner |
Insider | 844,787 | 9.02% | 2026-04-08 |
| Franklin Resources, Inc. | Institution (13G, 5%+) | 626,571 | 6.69% | 2025-12-31 |
| Woodline Partners LP | Institution (13F) | 625,000 | 6.68% | 2025-12-31 |
| Vanguard Group Inc | Institution (13F) | 291,277 | 3.11% | 2025-12-31 |
| Adage Capital Partners GP L.L.C. | Institution (13F) | 274,375 | 2.93% | 2025-12-31 |
| Prosight Management, Lp | Institution (13F) | 250,244 | 2.67% | 2025-12-31 |
| Renaissance Technologies, LLC | Institution (13F) | 242,945 | 2.60% | 2025-12-31 |
| Goldman Sachs Group Inc | Institution (13F) | 234,510 | 2.51% | 2025-12-31 |
| Stonepine Capital Management, LLC | Institution (13F) | 220,011 | 2.35% | 2025-12-31 |
| Lloyd Klickstein Chief Medical Officer, Director · +48,900 options |
Insider | 108,566 | 1.16% | 2025-06-11 |
| Steve Dubin Director · +30,600 options |
Insider | 22,700 | 0.24% | 2025-06-11 |
Share count 9,361,490 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2025-12-31). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-05 filed 2026-08-07 |
Klickstein Lloyd |
Option award (A) | 18,300 | – | – |
| 2026-06-21 filed 2026-06-23 |
Peng Katie |
Option award (A) | 4,200 | – | – |
| 2026-06-21 filed 2026-06-23 |
Klickstein Lloyd |
Option award (A) | 4,200 | – | – |
| 2026-06-21 filed 2026-06-23 |
Sinclair Andrew |
Option award (A) | 4,200 | – | – |
| 2026-06-21 filed 2026-06-23 |
Grissinger Michael |
Option award (A) | 4,200 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ACET and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →